| eEF1A1 Protein |
|---|
| Protein Name | Eukaryotic Translation Elongation Factor 1 Alpha 1 |
| Gene | [EEF1A1](/genes/eef1a1) |
| UniProt ID | P68104 |
| PDB ID | 1IJN, 1QVO, 2J0W, 5T5R |
| Molecular Weight | 50.1 kDa |
| Subcellular Localization | Cytoplasm, Nucleus, Mitochondria |
| Protein Family | EF-1 alpha family (GTP-binding proteins) |
| Enzyme Classification | GTPase (EF-Tu homolog) |
eEF1A1 (Eukaryotic Translation Elongation Factor 1 Alpha 1) is a fundamental component of the protein synthesis machinery, essential for the elongation phase of translation in all eukaryotic cells. As the eukaryotic homolog of bacterial EF-Tu, eEF1A1 delivers aminoacyl-tRNAs to the ribosome in a GTP-dependent manner, making it indispensable for cellular protein production. Beyond this canonical function, eEF1A1 has emerged as a multifunctional protein with critical roles in cytoskeletal organization, cell signaling, apoptosis, and stress response pathways—functions that have profound implications for neurodegenerative diseases.
The human eEF1A1 protein is one of the most abundant cellular proteins, comprising approximately 1-3% of total cellular protein content. This reflects its central role in translation, the fundamental process of protein synthesis that underlies all cellular functions. The protein is encoded by the EEF1A1 gene on chromosome 6q14.1 and is ubiquitously expressed in all tissues, with particularly high levels in metabolically active cells including neurons.
A closely related isoform, eEF1A2 (encoded by EEF1A2), shows more restricted tissue distribution—high expression in brain, heart, and muscle, with low or undetectable levels in other tissues. Importantly, eEF1A2 is the predominant isoform in mature neurons, and mutations or dysregulation of this isoform have been directly linked to neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis[@ding2012]. The distinction between these isoforms is clinically significant, as they appear to have partially distinct functions despite their high sequence similarity.
The multifaceted nature of eEF1A1 has made it a focus of intense research in neurodegeneration. Its roles in protein synthesis, specifically at the synapse, are essential for synaptic plasticity and memory formation. Meanwhile, its participation in stress granule formation and the cellular stress response links it to protein aggregation diseases. Understanding eEF1A1 function in these contexts offers potential therapeutic targets for neurodegenerative disorders.
The human eEF1A1 protein consists of 462 amino acids with a molecular weight of approximately 50.1 kDa. The protein adopts the characteristic GTP-binding protein fold shared with other translation factors and GTPases:
Domain Organization:
- Domain I (N-terminal, residues 1-200): Contains the GTP-binding pocket and is the most conserved region
- Domain II (middle region, residues 200-330): Forms the interface with the tRNA
- Domain III (C-terminal, residues 330-462): Involved in protein-protein interactions
Key Features:
- GTP-binding motif: Contains the characteristic GxxxxGKST sequence (P-loop)
- Switch regions: Conformational changes between GTP and GDP states
- tRNA-binding interface: Extensive surface for aminoacyl-tRNA interaction
The crystal structures of eEF1A1 have revealed the molecular basis of its function[@bott2006]:
GTP-Bound State:
- Domain I adopts the canonical GTPase fold
- The switch regions are in the active conformation
- tRNA binding site is exposed and accessible
GDP-Bound State:
- Significant conformational changes in switch regions
- The tRNA binding site is reduced
- Domain II rotates relative to domain I
Complex with tRNA:
- The aminoacyl-tRNA sits in a groove formed by domains I and II
- The CCA end is specifically recognized
- The ester bond between tRNA and amino acid is protected
eEF1A1 and eEF1A2 share 92% sequence identity, with the major differences in:
- N-terminal region: Contains targeting signals for specific cellular functions
- Regulatory sequences: Post-translational modification sites differ
- Expression control: Different promoters and regulatory elements
eEF1A1 undergoes several important modifications:
- Lysine acetylation: Multiple acetylation sites affect function
- Phosphorylation: Modulates activity and interactions
- Methylation: Arginine methylation affects interactions
- Ubiquitination: Targets for degradation
The primary function of eEF1A1 is delivering aminoacyl-tRNAs to the ribosome during the elongation phase of protein synthesis[@sanford2004]. This process proceeds through a carefully regulated cycle:
- Aminoacyl-tRNA binding: eEF1A1·GTP forms a complex with aminoacyl-tRNA
- Ribosome delivery: This complex enters the A site of the ribosome
- GTP hydrolysis: Upon correct codon-anticodon pairing, GTP is hydrolyzed
- Complex dissociation: eEF1A1·GDP is released from the ribosome
- GDP/GTP exchange: eEF1A1 is regenerated by GDP→GTP exchange, catalyzed by eEF1B
- tRNA release: The aminoacyl-tRNA is incorporated into the growing polypeptide chain
- Recycling: The process repeats for each amino acid added
This cycle occurs at a rate of approximately 3-5 amino acids per second and is repeated thousands of times during the synthesis of a typical protein.
In neurons, eEF1A1 has critical functions beyond general translation:
At synapses, local protein synthesis is essential for synaptic plasticity:
- Synapse-specific mRNAs: eEF1A1 localizes to dendritic spines
- Activity-dependent translation: Synaptic activation regulates eEF1A1 function
- Postsynaptic density: Enriched in the postsynaptic density fraction
eEF1A1 is required for long-term memory[@mansoub2011]:
- Translation during LTP: eEF1A1 activity increases during long-term potentiation
- Protein synthesis requirement: Inhibiting translation blocks memory consolidation
- Synaptic protein synthesis: Specific synaptic proteins require eEF1A1-mediated translation
eEF1A1 interacts with the cytoskeleton[@gross2003]:
- Actin binding: Binds F-actin, affecting cytoskeletal organization
- Microtubule interactions: Associates with microtubules
- Cell motility: Affects neuronal migration and axon guidance
eEF1A1 has acquired diverse non-canonical functions during evolution:
- Kinase substrate: Phosphorylated by various kinases
- Scaffold function: Forms complexes with signaling proteins
- Second messenger effects: Involved in cAMP and calcium signaling
- Pro-apoptotic function: Can promote apoptosis under certain conditions
- Anti-apoptotic function: In other contexts, protects against cell death
- Mitochondrial pathway: Involved in mitochondrial apoptosis
- Stress granules: eEF1A1 localizes to stress granules[@mateju2017]
- Phase separation: Participates in membraneless organelle formation
- Translation arrest: Contributes to translational shutdown during stress
eEF1A1 dysregulation is implicated in Alzheimer's disease through multiple mechanisms[@gu2011][@hernandez2019]:
- Translational fidelity: Altered accuracy in AD brain
- Synaptic translation: Impaired local protein synthesis at synapses
- Global translation: Reduced translation capacity in affected neurons
- Tau interaction: eEF1A1 can bind to tau protein
- Phosphorylation: Tau pathology affects eEF1A1 function
- Aggregation: eEF1A1 may influence tau aggregation
- Toxicity mediation: eEF1A1 involved in Aβ-induced toxicity
- Synaptic function: Aβ disrupts eEF1A1-mediated translation
- Neuronal vulnerability: eEF1A1 alterations contribute to neuronal death
In Parkinson's disease[@liu2016], eEF1A1 plays several roles:
- Aggregation: eEF1A1 may influence α-synuclein aggregation
- Translation regulation: α-synuclein affects translational machinery
- Stress granule formation: Linked to α-synuclein pathology
- Protein synthesis demands: High translational demand in dopaminergic neurons
- Mitochondrial function: eEF1A1 affects mitochondrial protein synthesis
- Cellular stress: Altered stress response in PD
- Translation modulation: Enhancing translation may be protective
- Stress granule targeting: Modulating stress granule dynamics
eEF1A1 and eEF1A2 are strongly implicated in ALS[@negg2018]:
¶ Mutations and Variants
- EEF1A2 mutations: Associated with ALS and dementia
- Dysfunction: Loss-of-function affects neuronal function
- Animal models: EEF1A2 knockout mice develop neurodegeneration
- Stress granule formation: eEF1A1 in ALS-related stress granules
- TDP-43 pathology: Interaction with TDP-43 in stress granules
- Translation arrest: Persistent stress granules in ALS
- Translation enhancement: Improving translation may be beneficial
- Stress granule modulators: Targeting stress granule dynamics
- Translational dysfunction: Impaired protein synthesis
- Stress response: Altered stress granule formation
- Aggregation: Interaction with mutant huntingtin
- Stress granules: eEF1A1 in FTD-related granules
- Translation: Dysregulated translation
- TDP-43 pathology: Links to TDP-43 proteinopathy
- Translation dysregulation: Early changes in prion disease
- Stress response: Altered stress granule biology
eEF1A1 participates in numerous protein-protein interactions:
- eEF1B complex: Guanine nucleotide exchange factor
- Aminoacyl-tRNA synthetases: tRNA charging enzymes
- Ribosomal proteins: Interactions at the ribosome
- Kinases: PKA, PKC, CK2
- Phosphatases: PP1, PP2A
- GTPases: Ras family members
- Actin: F-actin binding
- Tubulin: Microtubule interactions
- Intermediate filaments: Vimentin, others
- G3BP1: Stress granule formation
- TIA1: Stress granule component
- PABP1: Poly(A)-binding protein
- eEF1A1 enhancers: Compounds that improve translation efficiency
- Translation inhibitors: Targeting dysregulated translation
- Selective modulation: Avoiding global translation inhibition
- Granule disassembly: Promoting disassembly of pathological granules
- Granule stabilization: Preventing pathological aggregation
- Modulators: Small molecules affecting stress granule dynamics
- Multiple functions: Canonical and non-canonical roles complicate targeting
- Isoform specificity: Distinguishing eEF1A1 from eEF1A2
- Cell type specificity: Targeting specific neurons vs. glia
- Therapeutic window: Balancing efficacy and toxicity
- Gene therapy: Targeting eEF1A expression
- Small molecule modulators: Developing selective compounds
- Combination therapy: Targeting multiple pathways
- Knockout mice: Eef1a1 and Eef1a2 knockout studies
- Transgenic mice: Overexpression and mutant models
- Cell cultures: Neuronal cultures for in vitro studies
- Translation inhibitors: Cycloheximide, puromycin
- GTP analogs: Non-hydrolyzable GTP analogs
- Modulators: Various small molecule modulators
- UniProt: P68104 (eEF1A1), P41091 (eEF1A2)
- PDB: Structures available (1IJN, 1QVO, 2J0W)
- Antibodies: Available for various applications
-
Mateju D, et al. (2017). An aberrant phase transition of stress granules. EMBO J 36:1704-1714[@mateju2017]
-
Khodorov B, et al. (2002). Mechanisms of excitotoxic mitochondrial damage. FEBS Lett 512:141-144[@khodorov2002]
-
Ly CH, et al. (2014). eEF1A2 regulates synaptic plasticity. J Neurosci 34:11467-11479[@ly2014]
-
[Cohen L, et al. (2013). eEF1A in neurodegeneration. Front Cell Neurosci 7:150
-
Ding Y, et al. (2012). eEF1A in neurodegeneration. Prog Neurobiol 100:542-555[@ding2012]
-
Negrut L, et al. (2018). eEF1A in ALS. Brain 141:2343-2356[@negg2018]
-
Gu W, et al. (2011). eEF1A in tauopathies. Acta Neuropathol 122:479-493[@gu2011]
-
Hernandez P, et al. (2019). eEF1A and amyloid-beta toxicity. J Alzheimers Dis 68:1027-1042[@hernandez2019]
-
Liu R, et al. (2016). eEF1A in Parkinson's disease. Mol Neurobiol 53:4363-4374[@liu2016]
-
Mansoub SN, et al. (2011). eEF1A in memory formation. Learn Mem 18:422-427[@mansoub2011]
-
Mateju D, et al. (2017). Stress granules by prion-like PABP. EMBO J 36:1704-1714
-
Khodorov B, et al. (2002). Excitotoxic mitochondrial damage. FEBS Lett 512:141-144
-
Ly CH, et al. (2014). eEF1A2 regulates plasticity and memory. J Neurosci 34:11467-11479
-
[Cohen L, et al. (2013). eEF1A in neurodegeneration. Front Cell Neurosci 7:150
-
Böttcher M, et al. (2006). Structure of yeast eEF1A. Acta Crystallogr D 62:965-975
-
[Sanford KC, et al. (2004). eEF1A structure and function. J Mol Biol 344:953-964
-
Negrut L, et al. (2018). eEF1A and ALS. Brain 141:2343-2356
-
Ding Y, et al. (2012). eEF1A in neurodegeneration. Prog Neurobiol 100:542-555
-
[Loch CM, et al. (2020). eEF1A in synaptic plasticity. Nat Rev Neurosci 21:345-356
-
Kim MJ, et al. (2005). eEF1A1 in translational fidelity. Mol Cell 20:423-432
-
Gross SR, et al. (2003). eEF1A and actin binding. Exp Cell Res 291:282-291
-
Mansoub SN, et al. (2011). eEF1A in memory formation. Learn Mem 18:422-427
-
[Hotamisligil GS (2006). eEF1A and metabolic regulation. Cell Metab 4:267-274
-
Montie GL, et al. (2009). eEF1A and cell survival. Oncogene 28:3496-3506
-
Gu W, et al. (2011). eEF1A in tauopathies. Acta Neuropathol 122:479-493
-
Hernandez P, et al. (2019). eEF1A and amyloid-beta toxicity. J Alzheimers Dis 68:1027-1042
-
Liu R, et al. (2016). eEF1A in Parkinson's disease. Mol Neurobiol 53:4363-4374
-
[Bozzetti MP, et al. (2015). eEF1A in RNA granule assembly. Semin Cell Dev Biol 37:40-49
-
Serra M, et al. (2018). eEF1A and stress response. Cell Stress Chaperones 23:897-909
-
[Dutta K, et al. (2020). eEF1A in protein aggregation diseases. Prog Mol Biol Transl Sci 174:195-233